Wall Street analyst estimates for Humacyte, Inc. (HUMA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).
Analyst Consensus
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (1-5) | 0.91 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.09 | ||
| 2026-08-12 | $-0.16 | $-0.11 | -41.0% |
| 2026-05-13 | $-0.09 | $-0.10 | +10.0% |
| 2026-03-27 | $-0.13 | $-0.13 | +0.0% |
| 2025-11-12 | $-0.14 | $-0.17 | +17.6% |
| 2025-08-11 | $-0.24 | $-0.15 | -60.0% |
| 2025-05-13 | $0.28 | $-0.19 | +247.4% |
| 2025-03-28 | $-0.16 | $-0.24 | +33.3% |
Valuation Ratios
| Price / Book | 4.30 |
| EV / EBITDA | -1.10 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.2M | $1.5M | $1.3M | $1.6M | 0 | 0 | $2.0M |
| Cost of Revenue | $75.6M | $54.1M | $61.3M | $8.3M | $76.5M | $7.2M | $17.0M |
| Gross Profit | -$69.4M | -$52.6M | -$60.1M | -$6.7M | -$76.5M | -$7.2M | -$15.0M |
| Research & Development | $75.6M | $54.1M | $61.3M | $63.3M | $76.5M | $88.6M | $69.3M |
| Selling, General & Admin | $16.3M | $12.0M | $21.1M | $22.9M | $20.4M | $25.8M | $31.2M |
| Operating Expenses | $16.3M | $12.0M | $21.1M | $77.9M | $23.5M | $107.2M | $92.4M |
| Operating Income | -$85.7M | -$64.6M | -$81.2M | -$84.6M | -$100.0M | -$114.4M | -$107.4M |
| EBITDA | -$78.9M | -$56.2M | -$13.9M | $2.4M | -$96.5M | -$132.2M | -$22.2M |
| Interest Expense | $2.3M | $2.2M | $4.3M | $6.2M | $6.6M | $9.3M | $11.2M |
| Pre-tax Income | -$85.4M | -$66.5M | -$26.5M | -$12.0M | -$110.8M | -$148.7M | -$40.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$85.4M | -$66.5M | -$26.5M | -$12.0M | -$110.8M | -$148.7M | -$40.8M |
| EPS | $-4.25 | $-5.52 | $-0.66 | $-0.12 | $-1.07 | $-1.26 | $-0.26 |
| EPS (Diluted) | $-4.25 | $-5.52 | $-0.66 | $-0.12 | $-1.07 | $-1.26 | $-0.26 |
| Shares Outstanding (Diluted) | $103.0M | $12.4M | $40.0M | $103.1M | $103.4M | $118.5M | $158.2M |
Price
| Price | $0.57 |
| Market Cap | $96M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACHV · ARCT · AVIR · FHTX · IMRX · NAUT · SGMT
Explore sector: Healthcare · Biotechnology
More sections of HUMA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks